Viking Therapeutics, Inc. (VKTX)
28.34
-0.17
(-0.60%)
USD |
NASDAQ |
Oct 12, 16:00
28.29
-0.05
(-0.18%)
After-Hours: 20:00
Viking Therapeutics Net Income (Quarterly) : -128.02M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -128.02M |
| March 31, 2026 | -158.32M |
| December 31, 2025 | -157.66M |
| September 30, 2025 | -90.79M |
| June 30, 2025 | -65.56M |
| March 31, 2025 | -45.63M |
| December 31, 2024 | -35.42M |
| September 30, 2024 | -24.94M |
| June 30, 2024 | -22.25M |
| March 31, 2024 | -27.36M |
| December 31, 2023 | -24.60M |
| September 30, 2023 | -22.53M |
| June 30, 2023 | -19.22M |
| March 31, 2023 | -19.53M |
| December 31, 2022 | -19.56M |
| September 30, 2022 | -15.77M |
| June 30, 2022 | -17.43M |
| March 31, 2022 | -16.10M |
| December 31, 2021 | -12.36M |
| September 30, 2021 | -13.24M |
| June 30, 2021 | -15.38M |
| March 31, 2021 | -14.01M |
| December 31, 2020 | -10.95M |
| September 30, 2020 | -9.288M |
| June 30, 2020 | -9.572M |
| Date | Value |
|---|---|
| March 31, 2020 | -9.687M |
| December 31, 2019 | -7.45M |
| September 30, 2019 | -5.731M |
| June 30, 2019 | -7.674M |
| March 31, 2019 | -4.924M |
| December 31, 2018 | -5.24M |
| September 30, 2018 | -6.60M |
| June 30, 2018 | -6.672M |
| March 31, 2018 | -3.551M |
| December 31, 2017 | -4.084M |
| September 30, 2017 | -6.100M |
| June 30, 2017 | -5.172M |
| March 31, 2017 | -5.222M |
| December 31, 2016 | -3.645M |
| September 30, 2016 | -3.807M |
| June 30, 2016 | -3.693M |
| March 31, 2016 | -3.587M |
| December 31, 2015 | -5.091M |
| September 30, 2015 | -4.736M |
| June 30, 2015 | -7.865M |
| March 31, 2015 | -5.711M |
| June 30, 2014 | -22.78M |
| March 31, 2014 | -0.1507M |
| June 30, 2013 | -0.0224M |
| March 31, 2013 | -0.0046M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Eli Lilly & Co. | 7.095B |
| Regeneron Pharmaceuticals, Inc. | 1.297B |
| Amgen, Inc. | 2.375B |
| Vertex Pharmaceuticals, Inc. | 1.100B |
| Ironwood Pharmaceuticals, Inc. | 51.29M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 128.02M |
| EPS Diluted (Quarterly) | -1.101 |
| Enterprise Value | 2.808B |
| Earnings Yield | -16.45% |
| Normalized Earnings Yield | -16.45 |